PEPG

3.7803.82%
HM

Howard Mayer

Independent Director

Dr. Howard Mayer, M.D., serves as Director of Melmark, Inc. He is Member of Scientific & Clinical Advisory Board of Glycomine, Inc. Dr. Mayer serves as Director of Walden Biosciences, Inc since January 2025. He serves as Independent Director at PepGen Inc. since November 15, 2023. He serves as an Independent Director at Entasis Therapeutics Holdings Inc. since August 05, 2019. Dr. Mayer served as Chief Medical Officer of Shire plc since January 2018. Dr. Mayer was the Executive Vice President, Head of Research and Development for Ipsen Biopharmaceuticals, Inc. since 2019 until September 2023. Dr. Mayer serves on the Board of Adagio Therapeutics. Dr. Mayer served as Senior Vice President and Head of Global Clinical Development at Shire plc/Shire Pharmaceuticals from 2013 to 2018. Dr. Mayer joined Shire in 2012 and is responsible for global clinical development across hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas. Dr. Mayer served as Chief Medical Officer of U. S. organization at EMD Serono, Inc. since November 2009 and also served as its Head of US Department. Dr. Mayer responsibilities included oversight of the U.S. medical affairs group, U.S. medical operations, U.S. medical information, U.S. product surveillance and quality assurance and U.S. regulatory affairs. He joined EMD Serono from Pfizer's global research and development group, where he was Head of Clinical Development and Medical Affairs for Virology, focused on HIV and Hepatitis. Prior to joining Pfizer, he served as Director of Infectious Diseases Clinical Research at Bristol-Myers Squibb for many years. He had been an Independent Director of Genocea Biosciences, Inc. since March 06, 2017 until August 3, 2020. He serves on the scientific advisory boards of Macrolide Pharmaceuticals and Arsanis Biosciences and has served on the Board of Autism Speaks in New England since 2011 and on the Board of the Melmark Charitable Foundation since 2016. With his extensive clinical and commercial expertise in anti-infective drug development, he was recognized in 2011 as one of PharmaVoice’s 100 Most Inspiring People in the Life Sciences Industry. He has authored more than 70 publications and abstracts. Dr. Mayer has years of medical, clinical and executive experience in the life sciences industry. He had been Member of Scientific Advisory Board and Member of Clinical Advisory Board at Arsanis Inc. since January 12, 2017. Dr. Mayer was Senior Vice President and Global Head of R&D, Neuroscience Division at Shire Pharmaceuticals from 2018 to 2019. Dr. Mayer received his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at New England Deaconess Hospital and Harvard Medical School.

Positions